Special Issue: CAR-T Therapy: Clinical Progress

Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell has been used predominantly in the treatment of hematological malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma, and researchers and physicians worldwide are exploring the ever-evolving therapy in clinical settings.

Hematology and Oncology Discovery will publish a special issue 'CAR-T Therapy: Clinical Progress' to provide an overview of the CAR T-cell therapy research landscape, to showcase the wide applications of CAR-T therapy in the field of hematology, and to address the real-life difficulties for clinicians.

The collection will provide insights on applications of CAR-T cells in different hematological malignancies and pave the way for future improvement on the effectiveness and efficacy of this therapy.

Topics include:

- Application of CAR-T cell therapy for hematological malignancies
- Progress of CAR-T cell therapy for tumors
- Design for CAR-T clinical trials
- Technical progress in CAR-T cell cultures

Guest Editors

Tong Wu, MD, Beijing Boren Hospital, Beijing, China
Jing Pan, MD, Beijing Boren Hospital, Beijing, China

Further Information

For any further information, please contact the Editorial Office at Editorialoffice@hod-journal.org.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All submissions that pass pre-screening are peer-reviewed through the journal's standard -blind peer-review process.

For further information on article preparation please see Instructions for Authors.

Hematology and Oncology Discovery has **no** author submission or article processing charges.